Successful global anti-B-cell strategy with daratumumab in a patient with post-transplant nephrotic syndrome recurrence unresponsive to immunoadsorption and obinutuzumab.
Jean-Daniel DelbetJulien HoganCyrielle ParmentierTim UlinskiClaire DossierPublished in: Pediatric transplantation (2023)
A obinutuzumab and daratumumab combination seems to be a promising strategy in post-transplantation SRNS recurrence without response to standard treatment options.